Are there generic versions of Erdafitinib?
The original drug of Erdafitinib (Erdafitinib) has been launched in many countries. It is understood that there are also many countries overseas producing generic drugs of Erdafitinib. Its pharmaceutical ingredients are the same as those of the original drug. The ingredients of the drugs under development are basically the same, and they are suitable for the treatment of locally advanced or metastatic urothelial cancer with certain mutations. There may be slight differences in production specifications and prices. Common manufacturers of erdafitinib generic drugs include Bangladesh Yipin International, Laos ASEAN Pharmaceuticals, etc.
Erdafitinib is indicated for the treatment of locally advanced or metastatic urothelial carcinoma with predisposing FGFR-2 or FGFR-3 genomic aberrations (e.g., gene mutations, gene fusions) in patients during or following ≥ 1 prior platinum-containing therapy, including within 12 months of platinum-containing therapy in the neoadjuvant or adjuvant setting. Accelerated approval was based on an objective response rate of 32.2% in an adult cohort with relapsed or refractory locally advanced or metastatic urothelial cancer; in such patients, the historical objective response rate to second-line single-agent chemotherapy (e.g., taxanes, immune checkpoint inhibitors) is approximately 10–20%. Before initiating treatment, an FDA-approved companion diagnostic test is required to confirm the presence of FGFR genomic abnormalities.
The original version of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. The original version of erdafitinib currently sold in Hong Kong may cost more than 20,000 yuan per box of specifications 4mg*14 tablets (the price may fluctuate due to exchange rates). The generic drug of Erdafitinib produced by a Bangladesh pharmaceutical factory, with specifications of 4mg*60 tablets, may cost more than 3,000 yuan per box (the price may fluctuate due to the exchange rate). For more drug information and specific prices, please consult Yaode Medical Consultant.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)